We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Johnson & Johnson, Pfizer, Roche, AbbVie and Sanofi
Read MoreHide Full Article
For Immediate Release
Chicago, IL – October 22, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Johnson & Johnson (JNJ - Free Report) , Pfizer (PFE - Free Report) , Roche (RHHBY - Free Report) , AbbVie (ABBV - Free Report) and Sanofi (SNY - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Pharma Stock Roundup: Q3 Earnings Edition
This week, Johnson & Johnson began the third-quarter earnings season for the drug and biotech sector. The FDA granted approval to a few new drugs, which included Pfizer’s gene therapy for hemophilia, Roche’s breast cancer drug and AbbVie’s Parkinson’s treatment. Sanofi said it is considering selling a 50% stake in its consumer healthcare business (“CHC”), which it intends to separate.
Here's a recap of the week’s most important stories.
JNJ Begins Q3 Earnings Season
Johnson & Johnson’s third-quarter results were strong as it beat estimates for both earnings and sales. JNJ’s Innovative Medicines segment outperformed expectations while MedTech underperformed. Sales in Innovative Medicines segment rose 4.9% year over year to $14.58 billion. MedTech segment sales came in at $7.89 billion, up 5.8% from the year-ago period.
Johnson & Johnson’ raised its total revenue expectation for the year as it expects an improved performance in the rest of the year. However, the company lowered its adjusted earnings expectation as its expectation of a better operational performance was partially offset by costs associated with the recent acquisition of private medical device company V-Wave.
Total revenues are expected in the range of $88.4 billion-$88.8 billion for 2024, up from $88.0 billion-$88.4 billion expected previously. The adjusted earnings per share guidance was lowered from a range of $9.97-$10.07 to $9.88-$9.98 per share.
FDA Approves Pfizer’s New Hemophilia Gene Therapy
The FDA granted approval to Pfizer’s anti-TFPI inhibitor, marstacimab, for the treatment of hemophilia A and B. The drug will be marketed by the name of Hympavzi as a prophylactic treatment to prevent or reduce the frequency of bleeding episodes in adults and adolescents with hemophilia A or B without inhibitors. Hympavzi’s approval was based on positive data from the phase III BASIS study.
A marketing authorization application (MAA) for marstacimab is also under review in the EU. The European Commission’s decision on the MAA is expected by the first quarter of 2025. Hympavzi is Pfizer’s second hemophilia treatment to be approved this year. Beqvez/Durveqtix (fidanacogene elaparvovec), a one-time gene therapy for hemophilia B, was approved by the FDA in April 2024.
FDA Approves AbbVie’s New Parkinson’s Drug
The FDA approved AbbVie’s Vyalev (foscarbidopa and foslevodopa) for the treatment of motor fluctuations in adults with advanced Parkinson's disease (PD). Vyalev is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for advanced Parkinson's disease, which allows continuous delivery of levodopa in the morning, day and night. The approval was based on data from a pivotal phase III study, which compared the subcutaneous infusion of Vyalev to oral immediate-release carbidopa/levodopa.
The study data showed that patients who were treated with Vyalev experienced superior improvement in "on" time without troublesome dyskinesia versus oral medications. "On" time refers to the periods of time when patients are experiencing optimal motor symptom control. AbbVie said that Medicare is expected to cover the drug from the second half of 2025. Vyalev was launched by the name of Produodopa in the European Union in January.
FDA Approves Roche’s New Breast Cancer Drug
The FDA also approved Roche’s investigational breast cancer drug, inavolisib, to be sold under the brand name Itovebi. It is approved in combination with Pfizer’s Ibrance (palbociclib) and fulvestrant for treating advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation. Itovebi is Roche’s first targeted therapy approved for people with HR-positive disease, which is the most prevalent breast cancer subtype. The approval was based on data from the phase III INAVO120 study.
Sanofi Considering Sale of 50% Stake in Opella
Sanofi announced that it is in discussion to sell a 50% controlling stake in Opella, its CHC business. Sanofi announced its intention to separate its CHC unit last year through the creation of a publicly listed entity headquartered in Paris called Opella.
Sanofi is in negotiations with a U.S-based investment company, CD&R, for the potential sale of a controlling stake and an update will be provided when a final decision is made. With the separation of its consumer health unit, Sanofi joins several other large drugmakers like J&J, GSK and Pfizer, which have also sold off their consumer health units to focus on their core pharmaceuticals business.
The NYSE ARCA Pharmaceutical Index declined 0.5% in the last five trading sessions.
Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.
Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Johnson & Johnson, Pfizer, Roche, AbbVie and Sanofi
For Immediate Release
Chicago, IL – October 22, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Johnson & Johnson (JNJ - Free Report) , Pfizer (PFE - Free Report) , Roche (RHHBY - Free Report) , AbbVie (ABBV - Free Report) and Sanofi (SNY - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Pharma Stock Roundup: Q3 Earnings Edition
This week, Johnson & Johnson began the third-quarter earnings season for the drug and biotech sector. The FDA granted approval to a few new drugs, which included Pfizer’s gene therapy for hemophilia, Roche’s breast cancer drug and AbbVie’s Parkinson’s treatment. Sanofi said it is considering selling a 50% stake in its consumer healthcare business (“CHC”), which it intends to separate.
Here's a recap of the week’s most important stories.
JNJ Begins Q3 Earnings Season
Johnson & Johnson’s third-quarter results were strong as it beat estimates for both earnings and sales. JNJ’s Innovative Medicines segment outperformed expectations while MedTech underperformed. Sales in Innovative Medicines segment rose 4.9% year over year to $14.58 billion. MedTech segment sales came in at $7.89 billion, up 5.8% from the year-ago period.
Johnson & Johnson’ raised its total revenue expectation for the year as it expects an improved performance in the rest of the year. However, the company lowered its adjusted earnings expectation as its expectation of a better operational performance was partially offset by costs associated with the recent acquisition of private medical device company V-Wave.
Total revenues are expected in the range of $88.4 billion-$88.8 billion for 2024, up from $88.0 billion-$88.4 billion expected previously. The adjusted earnings per share guidance was lowered from a range of $9.97-$10.07 to $9.88-$9.98 per share.
FDA Approves Pfizer’s New Hemophilia Gene Therapy
The FDA granted approval to Pfizer’s anti-TFPI inhibitor, marstacimab, for the treatment of hemophilia A and B. The drug will be marketed by the name of Hympavzi as a prophylactic treatment to prevent or reduce the frequency of bleeding episodes in adults and adolescents with hemophilia A or B without inhibitors. Hympavzi’s approval was based on positive data from the phase III BASIS study.
A marketing authorization application (MAA) for marstacimab is also under review in the EU. The European Commission’s decision on the MAA is expected by the first quarter of 2025. Hympavzi is Pfizer’s second hemophilia treatment to be approved this year. Beqvez/Durveqtix (fidanacogene elaparvovec), a one-time gene therapy for hemophilia B, was approved by the FDA in April 2024.
FDA Approves AbbVie’s New Parkinson’s Drug
The FDA approved AbbVie’s Vyalev (foscarbidopa and foslevodopa) for the treatment of motor fluctuations in adults with advanced Parkinson's disease (PD). Vyalev is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for advanced Parkinson's disease, which allows continuous delivery of levodopa in the morning, day and night. The approval was based on data from a pivotal phase III study, which compared the subcutaneous infusion of Vyalev to oral immediate-release carbidopa/levodopa.
The study data showed that patients who were treated with Vyalev experienced superior improvement in "on" time without troublesome dyskinesia versus oral medications. "On" time refers to the periods of time when patients are experiencing optimal motor symptom control. AbbVie said that Medicare is expected to cover the drug from the second half of 2025. Vyalev was launched by the name of Produodopa in the European Union in January.
FDA Approves Roche’s New Breast Cancer Drug
The FDA also approved Roche’s investigational breast cancer drug, inavolisib, to be sold under the brand name Itovebi. It is approved in combination with Pfizer’s Ibrance (palbociclib) and fulvestrant for treating advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation. Itovebi is Roche’s first targeted therapy approved for people with HR-positive disease, which is the most prevalent breast cancer subtype. The approval was based on data from the phase III INAVO120 study.
Sanofi Considering Sale of 50% Stake in Opella
Sanofi announced that it is in discussion to sell a 50% controlling stake in Opella, its CHC business. Sanofi announced its intention to separate its CHC unit last year through the creation of a publicly listed entity headquartered in Paris called Opella.
Sanofi is in negotiations with a U.S-based investment company, CD&R, for the potential sale of a controlling stake and an update will be provided when a final decision is made. With the separation of its consumer health unit, Sanofi joins several other large drugmakers like J&J, GSK and Pfizer, which have also sold off their consumer health units to focus on their core pharmaceuticals business.
The NYSE ARCA Pharmaceutical Index declined 0.5% in the last five trading sessions.
Large Cap Pharmaceuticals Industry 5YR % Return
In the last five trading sessions, Johnson & Johnson rose the most (2.4%), while AbbVie declined the most (3.0%).
In the past six months, while Lilly rose the most (26.3%), Merck declined the most (12.7%).
(See the last pharma stock roundup here: FDA Approves SNY’s Dupixent for COPD & More)
What's Next in the Pharma World?
Watch this space for Sanofi and Roche’s third-quarter earnings update and regular pipeline and regulatory updates next week.
Pfizer, AbbVie, JNJ, Roche and Sanofi have a Zacks Rank #3 (Hold) each. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.